首页> 美国卫生研究院文献>BMC Cancer >Real-world effectiveness of post-trastuzumab emtansine treatment in patients with HER2-positive unresectable and/or metastatic breast cancer: a retrospective observational study (KBCSG-TR 1917)

【2h】

Real-world effectiveness of post-trastuzumab emtansine treatment in patients with HER2-positive unresectable and/or metastatic breast cancer: a retrospective observational study (KBCSG-TR 1917)

机译：HER2-阳性不可切除和/或转移性乳腺癌患者术后曲折南方疗效治疗的真实效力：回顾性观察研究（KBCSG-TR 1917）

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

The online version contains supplementary material available at 10.1186/s12885-021-08504-1.

机译：在线版本包含10.1186 / s12885-021-08504-1可用的补充材料。

著录项

期刊名称 BMC Cancer
作者
Takahiro Nakayama; Tetsuhiro Yoshinami; Hiroyuki Yasojima; Nobuyoshi Kittaka; Masato Takahashi; Shoichiro Ohtani; Seung Jin Kim; Hiroyuki Kurakami; Naoko Yamamoto; Tomomi Yamada; Takehiko Takata; Norikazu Masuda;
展开▼
作者单位

展开▼
年(卷),期 2021(-1),-1
年度 2021
页码 -1
总页数 12
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

机译：回顾性观察研究;HER2阳性;不可切除和/或转移性乳腺癌;KBCSG-TR 1917;T-DM1 / TRASTUZIMAB OMUNSINE;
入库时间 2022-08-21 12:18:02

相似文献

外文文献
中文文献
专利

1. Real-world effectiveness of post-trastuzumab emtansine treatment in patients with HER2-positive, unresectable and/or metastatic breast cancer: a retrospective observational study (KBCSG-TR 1917) [J] . Nakayama Takahiro, Yoshinami Tetsuhiro, Yasojima Hiroyuki, BMC Cancer . 2021,第1期

机译：患有Her2阳性，不可切除和/或转移性乳腺癌患者术后曲折南方疗养治疗的现实世界效力：回顾性观察研究（KBCSG-TR 1917）
2. Cardiac events in patients with HER2-positive metastatic breast cancer who have low left ventricular ejection fraction prior to initiating treatment with ado-trastuzumab emtansine: A retrospective cohort study using electronic health record data [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：在用Ado-Trastuzumab Omtansine启动治疗之前具有低左心室喷射乳腺癌的Her2阳性转移性乳腺癌患者的心脏事件：使用电子健康记录数据进行回顾性队列研究
3. Clinical benefit of treatment after trastuzumab emtansine for HER2-positive metastatic breast cancer: a real-world multi-centre cohort study in Japan (WJOG12519B) [J] . Takamichi Yokoe, Sasagu Kurozumi, Kazuki Nozawa, Breast cancer . 2021,第3期

机译：HERS2阳性转移性乳腺癌曲妥珠单抗治疗后治疗的临床益处：日本现实世界多中心队列研究（WJOG12519B）
4. Elevated WBP2 Expression in HER2-Positive Breast Cancers Correlates with Sensitivity to Trastuzumab-Based Neo-Adjuvant Therapy: A Retrospective and Multicentric Study [C] . Yoon Pin Lim International Molecular Medicine Tri-Conference. . 2019

机译：HER2阳性乳腺癌中的WBP2表达升高与基于曲妥珠单抗的新辅助治疗的敏感性相关：回顾性和多中心研究
5. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
6. Pyrotinib versus trastuzumab emtansine for HER2-positive metastatic breast cancer after previous trastuzumab and lapatinib treatment: a real-world study [O] . Feng Li, Fengrui Xu, Jianbin Li, 2021

机译：Pyrotinib与Hersutuzumab患者为Her2阳性转移性乳腺癌后的曲妥替尼对其进行了胸膜瘤和拉帕替尼治疗：一个真实的研究
7. Pyrotinib versus trastuzumab emtansine for HER2-positive metastatic breast cancer after previous trastuzumab and lapatinib treatment: a real-world study [O] . Feng Li, Fengrui Xu, Jianbin Li, 2021

机译：Pyrotinib与Hersutuzumab患者为Her2阳性转移性乳腺癌后的曲妥替尼对其进行了胸膜瘤和拉帕替尼治疗：一个真实的研究

Real-world effectiveness of post-trastuzumab emtansine treatment in patients with HER2-positive unresectable and/or metastatic breast cancer: a retrospective observational study (KBCSG-TR 1917)

摘要

著录项

相似文献

相关主题

期刊订阅